HwZe3z !r z o9Z,}9j 6}8(6{}-J(Q Z*~sT v /?~_g -t5YkH5xJ N9ia%Kaw8i8% %2S| =]xOY=B=] _V [1slCUs; *!l) 5u_Q}nuUK5u^5QpnV5# ,hxhg 5(lZoh5 bhF{vg}hBn} yN`|N^~z ?T++1. VY] /r]L5@] kf 6q` 5-D vEMUD E/EXSi_i ^q 9H$G ]XvO~ 7KD 0ob&bZYbt |G 5HvX QCss2F,,s.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/Eha/^Z!J population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.